NASDAQ:NOVN

Novan - NOVN Stock Forecast, Price & News

$1.76

-0.08 (-4.35%)

(As of 09/23/2022 08:56 PM ET)

Add

Compare

Today's Range: $1.67
▼
$1.83
50-Day Range: $1.76
▼
$3.03
52-Week Range: $1.67
▼
$8.94

Volume: 161,000 shs
Average Volume: 150,143 shs
Market Capitalization: $37.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Novan MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 752.3% Upside
$15.00 Price Target
Short Interest: Healthy
2.68% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.73) to ($1.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

631st out of 1,075 stocks

Pharmaceutical Preparations Industry

293rd out of 532 stocks

3.5

Analyst's Opinion

Consensus Rating
Novan has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Novan has a forecasted upside of 752.3% from its current price of $1.76.
Amount of Analyst Coverage
Novan has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.68% of the outstanding shares of Novan have been sold short.
Short Interest Ratio / Days to Cover
Novan has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Novan has recently decreased by 0.51%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Novan does not currently pay a dividend.
Dividend Growth
Novan does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NOVN.

2.1

News and Social Media Coverage

News Sentiment
Novan has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Novan this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for NOVN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Novan to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novan insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Novan is held by insiders.
Percentage Held by Institutions
Only 15.65% of the stock of Novan is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Novan are expected to grow in the coming year, from ($1.73) to ($1.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novan is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novan is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Novan has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Novan (NASDAQ:NOVN) Stock

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Stock News Headlines

September 22, 2022 | globenewswire.com

Outlook on the Acne Treatment Global Market, to 2027 - Rising Public Knowledge of Cosmetic Acne Treatments is Driving Growth - GlobeNewswire

September 15, 2022 | streetinsider.com

EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference - StreetInsider.com

September 15, 2022 | benzinga.com

Novan (NASDAQ:NOVN) – Novan Announces That EPI Health, A Novan Company, And MC2 Therapeutics Presented Da - Benzinga

September 15, 2022 | globenewswire.com

EPI Health, a Novan Company, and MC2 Therapeutics Present - GlobeNewswire

September 5, 2022 | reuters.com

NOVN.OQ - Novan Inc | Stock Price & Latest News | Reuters

August 30, 2022 | finance.yahoo.com

Genital Warts Market Size to Register Subsequent Growth by 2032 as Key Players Such as Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., and others are Looking for Opportunities | DelveInsight - Yahoo Finance

August 28, 2022 | reuters.com

NOVN.A - Novan Inc | Stock Price & Latest News | Reuters

August 17, 2022 | benzinga.com

NOVN: EPI Revenue Trends Are Strong - Benzinga

August 13, 2022 | greenwichtime.com

Novan: Q2 Earnings Snapshot - Greenwich Time

August 12, 2022 | finance.yahoo.com

Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance

August 11, 2022 | benzinga.com

Preparing and Aligning Your Biotech Organization for Commercial Success, Upcoming Webinar Hosted by Xtalk - Benzinga

August 11, 2022 | globenewswire.com

Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswire

August 10, 2022 | seekingalpha.com

Novan Q2 2022 Earnings Preview (NASDAQ:NOVN) - Seeking Alpha

July 21, 2022 | bizjournals.com

Novan phase 3 trial results published in JAMA amid FDA push - Triangle Business Journal - The Business Journals

July 19, 2022 | finance.yahoo.com

Global Acne Treatment Market, By Therapeutic Class, By Formulation, By Type, By Acne Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 - Yahoo Finance

July 19, 2022 | seekingalpha.com

Novan stock gains; Oppenheimer begins coverage at Outperform on SB206's market potential - Seeking Alpha

July 19, 2022 | globenewswire.com

Novan Satisfies $16.5 Million Outstanding Promissory Note - GlobeNewswire

July 13, 2022 | finance.yahoo.com

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology - Yahoo Finance

July 13, 2022 | benzinga.com

Novan Announces Publication Of Results From Pivotal Phase 3 Study Of Berdazimer Gel, 10.3% (SB206) In Patients With Molluscum Contagiosum In JAMA Dermatology - Benzinga

June 15, 2022 | globenewswire.com

Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market - GlobeNewswire

June 14, 2022 | nasdaq.com

Health Care Sector Update for 06/14/2022: NOVN,OM,ALNY,RKLY - Nasdaq

June 10, 2022 | finance.yahoo.com

Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market - Yahoo Finance

June 9, 2022 | globenewswire.com

Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market - GlobeNewswire

May 28, 2022 | benzinga.com

NOVN: First EPI Sales - Benzinga

May 23, 2022 | finance.yahoo.com

NOVN: First EPI Sales

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NOVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter.

NOVN Company Calendar

Last Earnings: 8/11/2022
Today: 9/26/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NOVN
CUSIP: N/A
CIK: 1467154
Web: www.novan.com
Phone: (919) 485-8080
Fax: 919-237-9212
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +752.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,690,000.00
Net Margins: -390.11%
Pretax Margin: -390.11%
Return on Equity: -236.13%
Return on Assets: -40.05%

Debt

Debt-to-Equity Ratio: 1.35
Current Ratio: 1.40
Quick Ratio: 1.37

Sales & Book Value

Annual Sales: $2.96 million
Price / Sales: 12.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.97 per share
Price / Book: 1.81

Miscellaneous

Outstanding Shares: 21,282,000
Free Float: 20,856,000
Market Cap: $37.46 million
Optionable: Not Optionable
Beta: 0.37

Key Executives

Ms. Paula Brown Stafford M.P.H. (Age 57)
Pres, CEO & Chairwoman
Comp: $1.01M

Mr. John M. Gay CPA (Age 46)
CFO & Corp. Sec.
Comp: $482.26k

Mr. Brian M. Johnson (Age 56)
Chief Commercial Officer
Comp: $443k

Mr. John A. Donofrio Jr. (Age 55)
Exec. VP, COO & Pres of EPI Health

Mr. Andrew J. Novak
VP of Accounting & Bus. Operations and Chief Accounting Officer

Dr. Carri Geer Ph.D.
Sr. VP & CTO

Mr. Cole Ikkala
Director of Investor Relations, Communications & Bus. Devel.

Mr. Stanley Hollenbach BS
J.D., Sr. VP of R&D

Dr. Tomoko Maeda-Chubachi M.B.A.
M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NOVN Stock - Frequently Asked Questions

Should I buy or sell Novan stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NOVN shares.
View NOVN analyst ratings or view top-rated stocks.
What is Novan's stock price forecast for 2022?: 3 Wall Street analysts have issued 1-year price targets for Novan's shares. Their NOVN share price forecasts range from $12.00 to $17.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 752.3% from the stock's current price.
View analysts price targets for NOVN or view top-rated stocks among Wall Street analysts.
How have NOVN shares performed in 2022?: Novan's stock was trading at $4.17 at the beginning of 2022. Since then, NOVN shares have decreased by 57.8% and is now trading at $1.76.
View the best growth stocks for 2022 here.
When is Novan's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our NOVN earnings forecast.
How were Novan's earnings last quarter?: Novan, Inc. (NASDAQ:NOVN) posted its quarterly earnings results on Thursday, August, 11th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.15. The business earned $6.16 million during the quarter, compared to the consensus estimate of $6.66 million. Novan had a negative net margin of 390.11% and a negative trailing twelve-month return on equity of 236.13%.
What other stocks do shareholders of Novan own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and OrganiGram (OGI).

When did Novan IPO?: (NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
What is Novan's stock symbol?: Novan trades on the NASDAQ under the ticker symbol "NOVN."
Who are Novan's major shareholders?: Novan's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.63%), B. Riley Wealth Management Inc. (0.37%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James L Bierman, John M Gay, John W Palmour and Paula B Stafford.
View institutional ownership trends.
How do I buy shares of Novan?: Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Novan's stock price today?: One share of NOVN stock can currently be purchased for approximately $1.76.
How much money does Novan make?: Novan (NASDAQ:NOVN) has a market capitalization of $37.45 million and generates $2.96 million in revenue each year. The company earns $-29,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.
How can I contact Novan?: Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The official website for the company is www.novan.com. The company can be reached via phone at (919) 485-8080, via email at cikkala@novan.com, or via fax at 919-237-9212.

This page (NASDAQ:NOVN) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

Novan - NOVN Stock Forecast, Price & News

Novan MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows